Medication info
Sitadown Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Sitadown Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
Hyundai Pharm Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202102463 · Approved 2021.03.19 · Insurance code 642004970

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Hyundai Pharm Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be administered as monotherapy in initial treatment, and if blood sugar control is insufficient, it may be combined with metformin. Additionally, when blood sugar control remains difficult after monotherapy with sulfonylureas, thiazolidinediones, or insulin, this medication can be added for combination therapy. In cases where multiple medications do not sufficiently improve blood sugar control, combination therapy including this medication improves blood sugar control effectively due to its flexible use across various treatment stages.

How to take

Adult dose

This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.

Precautions

This medication can cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur after administration, discontinue use immediately and consult a physician. Pancreatitis, a severe inflammation of the pancreas, may occur during treatment with this medication, so if symptoms like abdominal pain, nausea, or vomiting occur, seek medical attention immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients who are allergic to this medication or its components. Patients with impaired kidney function may have difficulty excreting the medication, so dose adjustments should be made under medical supervision. The risk of hypoglycemia may increase when this medication is used in combination with other diabetes treatments, so careful monitoring is required to prevent hypoglycemic symptoms. Patients may experience severe joint pain during treatment with this medication, and any such symptoms should be reported to a physician, who may consider discontinuation of the medication if necessary. If blisters or rashes develop on the skin, report it to a physician immediately and receive appropriate diagnosis and treatment. Pregnant or breastfeeding women are advised not to use this medication, and safety has not been established for children and adolescents under 18 years of age. Elderly patients may experience decreased kidney function, so regular kidney function tests and dose adjustments are recommended. In case of overdose, seek medical attention immediately, as this medication can be partially removed through dialysis. There may be interactions when taking this medication with certain other drugs, so inform your physician or pharmacist if you are taking any other medications.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe pain in joints accompanied by disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, increased low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air and moisture ingress, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.